Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$21.33
+2.8%
$17.10
$9.57
$27.34
$2.95B0.942.31 million shs2.65 million shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$49.08
-2.3%
$45.88
$21.72
$51.86
$9.38B1.232.93 million shs1.49 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$27.12
+3.4%
$29.18
$23.15
$84.28
$10.55B1.838.39 million shs9.16 million shs
QIAGEN N.V. stock logo
QGEN
QIAGEN
$49.71
+1.2%
$48.61
$37.63
$51.88
$11.06B0.641.34 million shs882,883 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
0.00%+4.00%+31.18%+40.98%-15.49%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%-4.36%+7.49%+47.21%+92.02%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-3.21%-20.26%+3.27%-68.70%
QIAGEN N.V. stock logo
QGEN
QIAGEN
0.00%+0.72%-3.08%+18.17%+8.68%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
3.7617 of 5 stars
3.51.00.03.42.82.50.0
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
4.6773 of 5 stars
4.52.00.03.92.73.30.6
Moderna, Inc. stock logo
MRNA
Moderna
4.5103 of 5 stars
4.02.00.04.62.62.50.6
Qiagen N.V. stock logo
QGEN
Qiagen
3.8292 of 5 stars
1.12.01.74.53.61.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
3.00
Buy$43.14102.26% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
3.00
Buy$61.3525.01% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$42.8858.12% Upside
QIAGEN N.V. stock logo
QGEN
QIAGEN
2.27
Hold$49.69-0.06% Downside

Current Analyst Ratings Breakdown

Latest ARWR, MRNA, QGEN, and BBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$18.00 ➝ $15.00
8/11/2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/11/2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00
8/8/2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$40.00 ➝ $38.00
8/7/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
8/7/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$48.00 ➝ $50.00
8/6/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$55.00 ➝ $57.00
8/6/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$60.00 ➝ $61.00
8/4/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$40.00 ➝ $31.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$32.00
8/1/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$26.00
(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$3.55M830.73N/AN/A$1.54 per share13.85
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$221.90M42.28N/AN/A($7.71) per share-6.37
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.26N/AN/A$28.33 per share0.96
QIAGEN N.V. stock logo
QGEN
QIAGEN
$1.98B5.59$3.20 per share15.52$16.05 per share3.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$599.49M-$1.28N/AN/AN/AN/A-40.91%-11.62%N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$535.76M-$4.090.00N/AN/A-329.25%N/A-85.69%11/11/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$7.530.00N/AN/A-94.31%-25.96%-20.09%11/6/2025 (Estimated)
QIAGEN N.V. stock logo
QGEN
QIAGEN
$83.59M$1.6921.2020.212.6118.30%14.77%8.87%11/5/2025 (Estimated)

Latest ARWR, MRNA, QGEN, and BBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q3 2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$0.94-$1.26-$0.32-$1.26$29.01 million$27.77 million
8/5/2025Q2 2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.83-$0.95-$0.12-$0.95$98.46 million$110.57 million
8/5/2025Q2 2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.60$0.60N/A$0.44$523.97 million$533.54 million
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.250.50%N/A14.79%N/A

Latest ARWR, MRNA, QGEN, and BBIO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/1/2025
QIAGEN N.V. stock logo
QGEN
QIAGEN
$0.250.52%7/2/20257/3/20257/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
0.39
4.87
4.87
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
5.19
5.08
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.93
3.77
Qiagen N.V. stock logo
QGEN
Qiagen
0.25
1.61
1.35

Institutional Ownership

CompanyInstitutional Ownership
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
62.61%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
QIAGEN N.V. stock logo
QGEN
QIAGEN
70.00%

Insider Ownership

CompanyInsider Ownership
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
4.30%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
18.20%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
QIAGEN N.V. stock logo
QGEN
QIAGEN
9.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
400138.26 million132.31 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400191.17 million156.38 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800389.08 million346.28 millionOptionable
QIAGEN N.V. stock logo
QGEN
QIAGEN
5,765222.29 million202.29 millionOptionable

Recent News About These Companies

Invesco Ltd. Purchases 53,383 Shares of Qiagen N.V. $QGEN
Qiagen: Diagnostics Vs. Life Sciences Pair Trade Analysis
Kepler Capital Remains a Hold on Qiagen (QGEN)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arrowhead Pharmaceuticals stock logo

Arrowhead Pharmaceuticals NASDAQ:ARWR

$21.33 +0.58 (+2.80%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$21.35 +0.02 (+0.08%)
As of 08/22/2025 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$49.08 -1.15 (-2.29%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$49.52 +0.45 (+0.91%)
As of 08/22/2025 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Moderna stock logo

Moderna NASDAQ:MRNA

$27.12 +0.90 (+3.43%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$27.13 +0.01 (+0.04%)
As of 08/22/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

QIAGEN stock logo

QIAGEN NYSE:QGEN

$49.71 +0.58 (+1.19%)
Closing price 08/22/2025 03:59 PM Eastern
Extended Trading
$49.74 +0.02 (+0.04%)
As of 08/22/2025 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.